Navigation Links
Health Robotics Re-Acquires CytoCare's European Rights from B. Braun Melsungen AG for Undisclosed Consideration
Date:5/17/2010

BOZEN, SUD-TIROL, Italy, May 17, 2010 /PRNewswire/ -- Health Robotics and B. Braun Melsungen AG today announced that in exchange for undisclosed consideration, Health Robotics has re-acquired from B. Braun the exclusive marketing, sales, installation, implementation, interface, manufacturing, and technical support European rights for CytoCare, a robot designed to manufacture chemotherapy and hazardous IV Admixtures, and which rights B. Braun had previously acquired from Health Robotics in 2007 and 2008. This amendment to the prior agreements includes the transition of all CytoCare customer contracts from B. Braun to direct Health Robotics' technical support starting on July 1st, 2010.

"Health Robotics' current global dominance of the IV Robotics industry is in great part due to the support we received from B. Braun since 2006. We learnt a lot from B. Braun through the last 42 months, especially in the area of flexibility supporting many different IV consumables, which has improved our robots not only for B. Braun's IV Bottles but also for Asia Pacific-based IV consumables. We will always owe a debt of gratitude to B. Braun and we hope to continue with B. Braun the joint cooperation in IV consumables, as we expand Health Robotics to directly market and support selected European countries in the next development phase for the company," stated Werner Rainer, Health Robotics' CEO.

In addition to the above mentioned undisclosed consideration, Health Robotics has agreed with B. Braun to continue to support B. Braun's market leading IV consumables such as Ecoflac Plus bottles, Easypump elastomeric devices, Excel and PAB I.V. Bags, Omnifix syringes, and TEC 1000 syringe caps, the latter being the only syringe cap supported by Health Robotics for its other, non hazardous IV robot: i.v.STATION.

"We also learnt a lot from this experience, especially as we expand B. Braun's horizons from its market-leading position in IV Therapy and Nutrition products into the complexity of Clinical IT solutions, requiring extensive Project Management skills at customers' locations," stated Dr. Torsten Doenhoff, B. Braun's Vice President Marketing & Sales Drug Admixture and Application Systems.

About B. Braun Melsungen AG:

B. Braun - Sharing Expertise. B. Braun supplies the global healthcare market with products for anaesthesia, intensive medicine, cardiology, extra corporeal blood treatment and surgery, as well as services for hospitals, general practitioners and the homecare sector. Through dialogue with those who are using B. Braun's products, the company is continually gaining new knowledge which it incorporates into product development. In this way, the company contributes with innovative products and services towards optimizing working procedures in hospitals and medical practices all over the world and improving safety - for patients, doctors and nursing staff.

With nearly 40,000 employees in 50 countries, B. Braun generated sales in 2009 of more than EUR 4bn. For more information please visit http://www.bbraun.com

About Health Robotics:

Health Robotics is the undisputed global leading supplier of life-critical intra-venous medication robots, providing healthcare facilities in 5 continents with robotics technology and software automation solutions. Its world-leading solutions CytoCare(TM) [hazardous IVs], i.v.STATION(TM) [non-hazardous IVs], i.v.SOFT(TM) [workflow engine for manual compounding, powered by MEDarchiver], and TPNstation(TM) [totally-automated parenteral nutrition] have and will greatly contribute to ease hospitals' growing pressures to improve patient safety, increase throughput and contain costs. Through the effective and efficient production of sterile, accurate, tamper-evident and ready-to-administer IVs, Health Robotics' solutions help hospitals eliminate life-threatening drug-exchange errors, decrease other therapy oversights and sterility risks, work more efficiently, reduce waste and controlled substances' diversion, and diminish the gap between rising patient volume/acuity and scarce nursing and pharmacy staff. For more information, please visit http://www.health-robotics.com

    For additional information, please contact:

    Health Robotics S.r.l.
    Claudia Flaim
    Marketing Coordinator
    Italy: +39-0471-200-372
    flaim@health-robotics.com

    B. Braun Melsungen AG
    Dr. Torsten Doenhoff
    Vice President Marketing & Sales Drug Admixture and Application Systems
    Germany: +49-5661-71-2714
    torsten.doenhoff@bbraun.com


'/>"/>
SOURCE Health Robotics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
3. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Tone Deafness Explained, from the Harvard Health Letter
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
8. ViroPharma to Present at Three Upcoming Healthcare Conferences
9. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
10. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, Inc., ... development and manufacturing of collagen and mineral based ... today that Bill Messer has joined ... to further leverage the growing portfolio of oral ... Bill joins the Collagen Matrix executive ...
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
(Date:6/24/2016)... ... 24, 2016 , ... People across the U.S. are sharpening their pencils and ... essay contest in which patients and their families pay tribute to a genetic counselor ... National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):